Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
timolol + brimonidine + dorzolamide + brinzolamide
- Development stage
- Phase 4
- Lead developer
- Laboratorios Sophia
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
A hypothetical quadruple combination of ophthalmic medications including timolol (a beta-blocker), brimonidine (an alpha-2 adrenergic agonist), and two carbonic anhydrase inhibitors (dorzolamide and brinzolamide). This exact combination does not appear to exist as a single commercial product. These agents work through different mechanisms to reduce intraocular pressure in patients with glaucoma or ocular hypertension.
02
Targets
CA2 (Carbonic Anhydrase 2)ADRA2A (α2A)ADRB1 (β1)CA (Carbonic anhydrase)
Beyond the preview
Go deeper on timolol + brimonidine + dorzolamide + brinzolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on timolol + brimonidine + dorzolamide + brinzolamide.